Wockhardt Ltd
NSE:WOCKPHARMA
Intrinsic Value
Wockhardt Ltd. engages in the pharmaceutical business. [ Read More ]
The intrinsic value of one WOCKPHARMA stock under the Base Case scenario is 206.3 INR. Compared to the current market price of 565.95 INR, Wockhardt Ltd is Overvalued by 64%.
Valuation Backtest
Wockhardt Ltd
Run backtest to discover the historical profit from buying and selling WOCKPHARMA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
This note will be permanently deleted.
Balance Sheet Decomposition
Wockhardt Ltd
Current Assets | 20.4B |
Cash & Short-Term Investments | 840m |
Receivables | 7.5B |
Other Current Assets | 12.1B |
Non-Current Assets | 53.8B |
Long-Term Investments | 620m |
PP&E | 23.5B |
Intangibles | 21.9B |
Other Non-Current Assets | 7.9B |
Current Liabilities | 26.9B |
Accounts Payable | 8B |
Short-Term Debt | 10.4B |
Other Current Liabilities | 8.5B |
Non-Current Liabilities | 16.1B |
Long-Term Debt | 11.7B |
Other Non-Current Liabilities | 4.4B |
Earnings Waterfall
Wockhardt Ltd
Revenue
|
27.8B
INR
|
Cost of Revenue
|
-11.8B
INR
|
Gross Profit
|
16B
INR
|
Operating Expenses
|
-16.6B
INR
|
Operating Income
|
-640m
INR
|
Other Expenses
|
-4.4B
INR
|
Net Income
|
-5B
INR
|
Free Cash Flow Analysis
Wockhardt Ltd
INR | |
Free Cash Flow | INR |
WOCKPHARMA Profitability Score
Profitability Due Diligence
Wockhardt Ltd's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
Score
Wockhardt Ltd's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
WOCKPHARMA Solvency Score
Solvency Due Diligence
Wockhardt Ltd's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Score
Wockhardt Ltd's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
WOCKPHARMA Price Targets Summary
Wockhardt Ltd
According to Wall Street analysts, the average 1-year price target for WOCKPHARMA is 450 INR .
Shareholder Return
WOCKPHARMA Price
Wockhardt Ltd
Average Annual Return | 4.89% |
Standard Deviation of Annual Returns | 83.16% |
Max Drawdown | -81% |
Market Capitalization | 80.6B INR |
Shares Outstanding | 153 400 992 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Wockhardt Ltd. engages in the pharmaceutical business. The company is headquartered in Mumbai, Maharashtra and currently employs 2,962 full-time employees. The firm's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. The company manufactures a range of dosage forms, including sterile injectables and lyophilized products. The firm offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Company’s products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. The firm has approximately three research centers globally and a chain of six super-specialty hospitals across Maharashtra and Gujarat.
Contact
IPO
Employees
Officers
The intrinsic value of one WOCKPHARMA stock under the Base Case scenario is 206.3 INR.
Compared to the current market price of 565.95 INR, Wockhardt Ltd is Overvalued by 64%.